My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

51.28 +0.10 (+0.20%)
Streaming Delayed Price Updated: 10:53 AM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
1 Profitable Stock for Long-Term Investors and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Out-of-Favor Stocks We Keep Off Our Radar
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Topics Firearms
Sherwin-Williams, Sealed Air, Super Micro, Globus Medical, and Haemonetics Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics ETFs Economy
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
3 Cash-Producing Stocks with Open Questions
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
HAE Q2 Deep Dive: Margin Expansion Amid Revenue Decline and Product Execution Challenges
Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10 per share was... 
Via StockStory
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
 
Via Benzinga
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Haemonetics Through 6 Analysts
 
Via Benzinga
Haemonetics (NYSE:HAE) Surprises With Strong Q2 But Stock Drops 24%
Blood products company Haemonetics (NYSE:HAE). reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10... 
Via StockStory
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Haemonetics (HAE) Q1 Revenue Falls 4%
Via The Motley Fool
Peering Into Haemonetics's Recent Short Interest
 
Via Benzinga
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics World Trade
Peering Into Haemonetics's Recent Short Interest
 
Via Benzinga
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
Unpacking Q1 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
Via StockStory
1 Healthcare Stock to Target This Week and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
3 Profitable Stocks Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Analyst Expectations For Haemonetics's Future
 
Via Benzinga
3 Russell 2000 Stocks Skating on Thin Ice
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Topics Economy
HAE Q1 Earnings Call: Revenue Misses Expectations, Margin Expansion and Product Focus Highlighted
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $330.6 million. Its non-GAAP EPS of $1.24 per share... 
Via StockStory
1 Value Stock to Target This Week and 2 to Question
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
What 4 Analyst Ratings Have To Say About Haemonetics
 
Via Benzinga
1 Healthcare Stock to Consider Right Now and 2 to Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
Haemonetics (NYSE:HAE) Surprises With Q1 Sales
Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 3.7% year on year to $330.6 million. Its non-GAAP profit of $1.24 per share was... 
Via StockStory
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
1 Profitable Stock Worth Your Attention and 2 to Question
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.